HUTCHMED (CHINA) LS-,10 Aktie

Hutchmed reported that the Phase-III study SAFFRON for ORPATHYS (Savolitinib) in combination with TAGRISSO (Osimertinib) significantly improved both progression-free survival and overall survival in patients with MET-driven, EGFR-resistant non-small-cell lung cancer. The stock climbed intraday by about 5% to HK$20.14, reaching its highest level since May 11. The global study included 338 patients; the result strengthens the case for worldwide regulatory filings and could extend the combination’s commercial prospects beyond China. » More on de.investing.com

China’s drug regulator has granted conditional approval for ORPATHYS (savolitinib) from HUTCHMED for the treatment of MET‑amplified advanced gastric cancer and gastroesophageal junction adenocarcinoma. The approval is based on a Phase II study showing an objective response rate of 32.3% and secondary endpoints including a disease control rate of 63.1% and a median progression‑free survival of 4.0 months. ORPATHYS is the first approval of a selective MET inhibitor for this patient group in China, is being developed jointly with AstraZeneca, and is already listed on the national reimbursement list. After the announcement, HUTCHMED’s shares rose sharply (around +6.5%). » More on de.investing.com

China’s drug regulator granted HUTCHMED conditional approval for ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification after at least two prior systemic therapies. The approval is based on a Phase II study in China showing an objective response rate of 32.3%, a disease control rate of 63.1% and a median progression‑free survival of 4.0 months. ORPATHYS is the first selective MET inhibitor approved in China for this indication; MET amplifications affect about 4–6% of patients (roughly 18,000 cases annually). The drug was co‑developed with AstraZeneca and is already listed on China’s reimbursement list. » More on de.investing.com

HUTCHMED presented positive phase‑III results from the ESLIM‑02 study on Sovleplenib for warm autoimmune hemolytic anemia at the EHA congress, meeting the primary endpoint (durable response rate weeks 5–24: 66% vs. 15% placebo). In the randomized trial the overall response rate was 70% versus 22% for placebo; rescue therapies and transfusions were needed much less often and the median time to response was faster at 3.1 weeks compared with placebo. A regulatory submission to the NMPA is under review and the program has already received breakthrough and priority review designations. » More on de.investing.com

HUTCHMED has applied to the London Stock Exchange for block admission of 43,616,756 ordinary shares to trading on AIM; the admission is expected to become effective on 11 June 2026. The shares will be issued on the exercise of options under the 2026 share option scheme, which was approved on 12 May 2026. After issuance, the new ordinary shares will be fully paid and rank pari passu with the existing shares; the total issued share capital will remain at 872,335,120 ordinary shares. The existing block admission under the 2015 option scheme, covering 45,768,368 shares, remains valid. » More on de.investing.com